PropThink: Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

PropThink: Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

[ACN Newswire] – By David SobekIn November of 2011, Gilead (NASDAQ:GILD) announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO John Martin noted , the … more

View todays social media effects on VRTX

View the latest stocks trending across Twitter. Click to view dashboard

Share this post